Please note the ANZCTR will be unattended from Friday 24 December 2021 for the holidays. The Registry will re-open on Monday 17 January 2022. Submissions and updates will not be processed during that time.

For new and updated trial submissions, we are processing trials as quickly as possible and appreciate your patience. We recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from

For full trial details, please see the original record at

Registration number
Ethics application status
Date submitted
Date registered
Date last updated

Titles & IDs
Public title
Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Doses of GSK580416
Scientific title
A Three Part Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of Repeat Escalating Oral Doses of GSK580416; the Safety, Tolerability, and Pharmacokinetics of GSK580416 Following a Loading Dose Regimen; and the Effect of Ketoconazole on the Pharmacokinetics of GSK580416
Secondary ID [1] 0 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Bacterial Infection 0 0
Infections, Bacterial 0 0
Condition category
Condition code
Infection 0 0 0 0
Studies of infection and infectious agents
Infection 0 0 0 0
Other infectious diseases
Infection 0 0 0 0
Sexually transmitted infections

Study type
Description of intervention(s) / exposure
Treatment: Drugs - GSK580416 oral tablets (250 mg) Ketoconazole oral tablets (200 mg)

Treatment: Drugs: GSK580416 oral tablets (250 mg) Ketoconazole oral tablets (200 mg)

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Primary outcome [1] 0 0
Safety and tolerability of GSK580416 doses determined from clinical safety and tolerability data from all adverse event reporting, 12-lead ECGs, vital signs, nursing/physician observation, and safety laboratory tests
Timepoint [1] 0 0
Secondary outcome [1] 0 0
Pharmacokinetics of GSK580416 as determined by AUC, Cmax, tmax, half-life, and Ct.
Timepoint [1] 0 0

Key inclusion criteria
- Healthy adults (as determined by medical evaluation including history, physical exam,
vital signs, laboratory tests, and cardiac monitoring)

- Aged 18-60yrs, with BMI of 19-31kg/m2.

- Females must be of non-childbearing potential.

- QTc < 450 msec at screening.

- Subjects must be able to give consent and comply with restrictions of study.
Minimum age
18 Years
Maximum age
64 Years
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
- Clinically significant CNS, cardiac, pulmonary, metabolic, renal, hepatic or GI
condition or history that may place the subject at an unacceptable risk or may
interfere with absorption, distribution, metabolism, or excretion of drug.

- Positive urine drug screen.

- Positive urine test for alcohol.

- Positive HIV or Hep B and/or C assay.

- History of regular tobacco use within 3 monts prior to screening or cotinine levels
indicative of smoking at screening.

- History of regular alcohol consumption (14 units/week for women and 21 units/week for

- History of drug abuse or dependence within 12 months of study.

- Participation in another drug trial within 30 days of first dose.

- Exposure to more than 4 new chemical entities within 12 months of first dose.

- Use of prescription and non-prescription drugs including vitamins, dietary
supplements, herbals within 7 days of first dose or St. John's Wort within 28 days of
the first dose.

- Consumption of red wine, Seville oranges, grapefruit, or grapefruit juices within 14
days of first dose.

- Donation of blood in excess of 500 mL within 56 days of dosing. No blood donation is
allowed 30 days prior to study participation.

- A positive immunochemical fecal occult blood test at screening.

- History of sensitivity to any of the study medications.

- History of sensitivity to heparin or heparin-induced thrombocytopenia.

- History of orthostatic hypotension or orthostatic hypotension at screening.

Study design
Purpose of the study
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?

Intervention assignment
Other design features
Phase 1
Type of endpoint(s)
Statistical methods / analysis

Recruitment status
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
GSK Investigational Site - Adelaide
Recruitment postcode(s) [1] 0 0
5000 - Adelaide

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry

Ethics approval
Ethics application status

Brief summary
This study will evaluate the safety, tolerability and exposure of repeat escalating oral
doses, a loading dose/maintenance dose regimen of GSK580416 and when co administered with
ketoconazole, a PGP/CYP3A4 inhibitor.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 0 0
GSK Clinical Trials
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
For IPD and results data, please see